ARCA biopharma (ABIO) Plans Adaptive Phase-3 for Gencaro - InvestingChannel

ARCA biopharma (ABIO) Plans Adaptive Phase-3 for Gencaro

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases … This article: 958 words

— Date Published: Jan 29, 2013 05:34PM — To continue reading this article and more like it please sign-in or join today (FREE!)